Abstract
In 2004, the US Food and Drug Administration (FDA) launched its Critical Path Initiative. Recognizing the increasingly complicated and difficult path to medical product development, the FDA concluded that it was very important to develop new tools to evaluate and predict the safety, efficacy and manufacturability of medical products. The FDA called for a national effort to identify specific activities all along the critical path of medical product development and use, which, if undertaken, would help transform the critical path sciences.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Path from Biomarker Discovery to Regulatory Qualification
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
